PDCD1 and Merkel cell skin cancer: Both VP-MCC and virus-negative (VN) MCC are inherently immunogenic and are among the most responsive solid tumors to PD-1 pathway blockade, with approximately 50% of patients achieving durable disease control [25,154,155,156,157].